Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

One in 10 clinics in SA — across 22 health districts in six provinces — could start to hand out a twice-a-year anti-HIV jab ...

One in 10 clinics in South Africa will start to hand out a twice-a-year anti-HIV jab as early as February. The country’s medicines regulator, Sahpra, says it’s on track to announce its registration ...

NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong activity against the Measles virus in cell culture ...

Now, the fight against HIV/AIDS is not just about governments and global health organisations anymore; it is a deeply personal one. And it is all about the choices you make, the conversations you have ...

BIC/TAF/FTC demonstrated a stronger long-term immunologic response than DTG/TDF/FTC in patients with HIV who had low CD4+ ...

There was no significant difference in virologic efficacy through 96 weeks in adults with HIV who switched to DTG/3TC vs ...

One in 10 clinics in South Africa—across 22 health districts in six provinces—could start to hand out a twice-a-year anti-HIV jab as early as ...

The challenge with curing the Human Immunodeficiency Virus (HIV) is that it tends to hide dormant in cells, evading the body’s natural immune system as well as some therapies. A new study uses novel ...

The antibody, called 04_A06, blocked 98.5% of more than 300 different HIV strains in lab tests, including many resistant to ...

According to the new study, HIV achieves this with a tissue-specific approach, cloaking itself in a host cell's DNA by ...

If someone becomes infected with HIV and does not seek timely treatment, the infection gradually progresses through three stages. Each stage has different symptoms and risks. HIV AIDS: If a person ...